Modifiable Cardiovascular Risk Factors Amongst Men With and Without Prostate Cancer in a Large, Prospective Registry
- 31 March 2025
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (3) , 102340
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30 CA008748)
- National Institutes of Health
- Prostate Cancer Foundation
- National Heart, Lung, and Blood Institute (5T32HL007745-30)
This publication has 8 references indexed in Scilit:
- Promoting integrated care in prostate cancer through online prostate cancer-specific holistic needs assessment: a feasibility study in primary careSupportive Care in Cancer, 2019
- Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-upNew England Journal of Medicine, 2018
- Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerationsProstate Cancer and Prostatic Diseases, 2018
- Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational StudiesPLOS ONE, 2014
- Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studiesProstate Cancer and Prostatic Diseases, 2012
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal InferencePolitical Analysis, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006